RESUMEN
INTRODUCTION: Imatinib is a first-line selective tyrosine kinase inhibitor used for the treatment of chronic myeloid leukemia. Although imatinib-induced hepatotoxicity may aggravate the patient's clinical condition and alter the treatment plan, the mechanism of imatinib-induced hepatotoxicity has rarely been investigated. CASE REPORT: We report a 51-year-old man, suffering from acute toxic hepatitis after 5 months of imatinib treatment for chronic myeloid leukemia. MANAGEMENT AND OUTCOME: The outcome was favorable after discontinuation of treatment with normalization of biological liver function after 12 weeks. The treatment was switched to nilotinib without any incidents. DISCUSSION: Regular liver function test monitoring is recommended during imatinib treatment. In fact of acute hepatic toxicity, treatment with imatinib should be stopped in the case of cytolysis more than five times the upper limit of normal.
Asunto(s)
Enfermedad Hepática Inducida por Sustancias y Drogas , Mesilato de Imatinib , Leucemia Mielógena Crónica BCR-ABL Positiva , Humanos , Masculino , Persona de Mediana Edad , Antineoplásicos/efectos adversos , Enfermedad Hepática Inducida por Sustancias y Drogas/etiología , Mesilato de Imatinib/efectos adversos , Leucemia Mielógena Crónica BCR-ABL Positiva/tratamiento farmacológico , Inhibidores de Proteínas Quinasas/efectos adversos , Resultado del TratamientoAsunto(s)
Anticonvulsivantes/efectos adversos , Linfohistiocitosis Hemofagocítica/inducido químicamente , Fenobarbital/efectos adversos , Anemia/etiología , Anticonvulsivantes/uso terapéutico , Enfermedades Autoinmunes/diagnóstico , Diagnóstico Diferencial , Síndrome de Hipersensibilidad a Medicamentos/diagnóstico , Epilepsia/tratamiento farmacológico , Neutropenia Febril/etiología , Femenino , Humanos , Hiperpigmentación/inducido químicamente , Pruebas de Función Hepática , Linfohistiocitosis Hemofagocítica/sangre , Linfohistiocitosis Hemofagocítica/diagnóstico , Neoplasias/diagnóstico , Fenobarbital/uso terapéutico , Virosis/diagnóstico , Adulto JovenRESUMEN
Drug rash with eosinophilia and systemic symptoms (DRESS syndrome) in a severe cutaneous drug reaction, which can be life threatening. Levofloxacin has not been reported in literature as a causative drug. We are presenting an exceptional case of levofloxacin-induced DRESS without eosinophilia and with positive patch-tests to levofloxacin.
Asunto(s)
Antibacterianos/efectos adversos , Síndrome de Hipersensibilidad a Medicamentos/etiología , Levofloxacino/efectos adversos , Pruebas del Parche , Acetaminofén/uso terapéutico , Adulto , Antibacterianos/administración & dosificación , Síndrome de Hipersensibilidad a Medicamentos/diagnóstico , Quimioterapia Combinada , Infecciones por Virus de Epstein-Barr/tratamiento farmacológico , Fluoroquinolonas/efectos adversos , Humanos , Levofloxacino/administración & dosificación , Pruebas de Función Hepática , Masculino , Metronidazol/administración & dosificación , Metronidazol/uso terapéutico , Fenoles/uso terapéutico , Infecciones del Sistema Respiratorio/tratamiento farmacológicoRESUMEN
We describe two cases of fixed drug eruptions induced by pheniramine (1(st) case) and loratadine (2(nd) case).
Asunto(s)
Erupciones por Medicamentos/etiología , Eritema/inducido químicamente , Antagonistas de los Receptores Histamínicos H1/efectos adversos , Erupciones por Medicamentos/patología , Eritema/patología , Antagonistas de los Receptores Histamínicos H1/administración & dosificación , Humanos , Hiperpigmentación/inducido químicamente , Hiperpigmentación/patología , Loratadina/administración & dosificación , Loratadina/efectos adversos , Masculino , Persona de Mediana Edad , Feniramina/administración & dosificación , Feniramina/efectos adversosRESUMEN
We describe two cases of fixed drug eruptions induced by pheniramine (1(st) case) and loratadine (2(nd) case).
Asunto(s)
Antineoplásicos/efectos adversos , Benzamidas/efectos adversos , Hipoproteinemia/inducido químicamente , Piperazinas/efectos adversos , Leucemia-Linfoma Linfoblástico de Células Precursoras/complicaciones , Pirimidinas/efectos adversos , Antineoplásicos/uso terapéutico , Benzamidas/uso terapéutico , Niño , Humanos , Mesilato de Imatinib , Masculino , Piperazinas/uso terapéutico , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamiento farmacológico , Pirimidinas/uso terapéuticoRESUMEN
Imatinib, an antineoplastic drug used to treat certain cancers, has many side effects such as hematologic, neurologic or cutaneous toxicity. These toxicities seem to be due to a high imatinib plasmatic concentration and are frequently controlled by a discontinuation or a dosage reduction of the drug. We report here in 2 cases of cutaneous side effects induced by imatinib in order to demonstrate the necessity of drug monitoring in such cases. In our cases, imatinib is responsible in the occurrence of these side effects. Monitoring plasma levels of imatinib allowed us to judge if levels were toxic or not and to avoid discontinuation of imatinib in some cases.